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Abstract
Background: The goal of the present study was the characterization of Plasmodium falciparum
genes associated to malaria drug resistance (pfcrt, pfdhfr and pfdhps), in samples from two Brazilian
localities.
Methods: Parasites from 65 P. falciparum samples were genotyped using nested-PCR and direct
DNA sequencing.
Results:  Six resistant sulphadoxine-pyrimethamine (SP) pfdhfr  genotypes and one haplotype
associated to SP sensitivity were detected. For pfcrt gene, SVMNT chloroquine (CQ)-resistant
genotype was detected as well as the CVMNK CQ-sensitive haplotype in the same sample from
Paragominas, that showed a SP-sensitive genotype.
Conclusion: This study is the first to document the sensitivity of P. falciparum parasites to CQ and
SP in Brazilian field samples. The importance of these findings is discussed.
Background
Malaria is a challenging infectious disease to many coun-
tries in the world, especially to those located in tropics
and subtropical regions, and the increasing numbers of
drug resistant parasites worsens this situation. In Brazil, as
well as in other endemic countries, drug-sensitivity tests
revealed that Plasmodium falciparum isolates displayed
high levels of resistance to many drugs, including chloro-
quine (CQ) and sulphadoxine-pyrimethamine (SP) [1-4].
The first documented case of CQ resistance in Brazil was
in 1954; in the sixties several authors in South America
(SA) reported the occurrence of in vivo falciparum malaria
resistance to CQ and amodiaquine. The spread of 4-
amino-quinoleine resistant strains of P. falciparum lead
also to the use of SP in the seventies. Unfortunately, at the
end of eighteens the SP resistance it was no less than 90%
[5] and at the beginning of nineties the CQ failure rate was
considered 100% [6] and, consequently, the Brazilian
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National Malaria Programme withdrew SP and CQ for fal-
ciparum malaria treatment. Then, the combination qui-
nine plus tetracycline was introduced, followed by the
usage of the combination quinine plus doxycycline or, as
second-line drug, mefloquine plus primaquine. In 2007,
a fixed combination of artemether plus lumefantrine
(Coartem®) was introduced as first-line drug [7] and since
2008, the fixed combination artesunate plus mefloquine
(FarManguinhos, Fiocruz) was produced, and its imple-
mentation in Brazilian endemic areas is in progress to
counteract parasite resistance, according to WHO guide-
lines [8].
Interestingly, the reemergence of CQ-sensitive P. falci-
parum parasites as well as the downturn of P. falciparum
triple mutants associated to SP resistance, were reported
after cessation of monotherapy using CQ or SP for the
treatment of P. falciparum malaria [9-13]. These findings
provide a rationale for the search of drug-sensitive haplo-
types in P. falciparum isolates in Brazilian areas where the
use of these two drugs for falciparum malaria treatment
has been interrupted since 1990.
The goal at the present study was, therefore, the character-
ization of pfcrt, pfdhfr and pfdhps genes that are known
molecular markers of P. falciparum resistance to CQ and
SP [14].
Methods
Study sites, blood samples and DNA extraction
Parasites from 65 P. falciparum samples were genotyped.
These samples were collected at the time of diagnosis from
uncomplicated malaria patients living in two Brazilian
malaria-endemic areas: Porto Velho – Rondônia state (n =
46), and Paragominas – Pará state (n = 19). After obtain-
ing the informed consent, venous blood collection was
done according to protocols previously approved by the
ethics research committees of Fiocruz and of local study
sites. DNA was extracted from 1 ml of cryopreserved
blood using QIAamp midi columns as described by the
manufacturer (Qiagen).
Polymerase chain reactions (PCRs) and electrophoresis
A nested-PCR technique was employed in order to
amplify a partial DNA sequence containing the major sin-
gle-nucleotide polymorphisms (SNPs) related to drug-
resistance for each target gene as: SNPs A16V/S, C50R,
N51I, C59R, S108N, V140L plus I164L for pfdhfr, S436A/
F/C, A437G, K540E, A581G plus A613T/S for pfdhps, and
SNPs C72S, M74I, N75E/D plus K76T for pfcrt. The proto-
cols of pfdhfr and pfdhps nested PCRs have been described
elsewhere [15]. The amplification of the pfcrt gene frag-
ment was performed with 5 μl of DNA into a 45 μl mix-
ture containing 2.5 mM of MgCl2, 250 μM of dNTPs, 1.25
units of Amplitaq Gold® DNA polymerase (Applied Bio-
systems), and 10 pmol of each primer (Alpha DNA):
CRTP1 (5' CCG TTA ATA ATA AAT ACA CGC AG 3') and
CRTP2 (5' CGG ATG TTA CAA AAC TAT AGT TAC C 3') to
amplify a 537 bp region. The reactions were settled with
an initial hold (95°C/10 minutes), 45 cycles (94°C/30
seconds, 56°C/30 seconds and 60°C/1 minute) plus one
final hold (60°C/3 minutes). Then, 5 μl of the first PCR
amplification were added to 45 μl of a second mixture
containing the second set of primers (Alpha DNA):
CRTD1 (5' TGT GCT CAT GTG TTT AAA CTT 3') and
CRTD2 (5' CAA AAC TAT AGT TAC CAA TTT TG 3') and
32 steps (1 hold 95°C/10 min, 30 cycles 92°C/30 sec,
48°C/30 sec and 65°C/30 sec, and 1 hold 65°C/3 min)
were performed to amplify a 134 bp fragment. PCR prod-
ucts were analysed by ethidium bromide-stained agarose-
gel (2%) electrophoresis.
DNA sequencing
After DNA purification using the Wizard SV Gel and PCR
Clean-Up System (Promega), the amplified fragments
were sequenced using Big Dye® Terminator Cycle Sequenc-
ing Ready Reaction version 3.1 (Applied Biosystems) and
ABI PRISM DNA Analyzer 3730 (Applied Biosystems)
from the Genomic Platform/PDTIS/Fiocruz [16].
Results
The pfcrt nested-PCR generated DNA fragments in all the
65 samples, the pfdhps  in 63 samples and the pfdhfr
nested-PCR in 52 samples, showing different sensitivity
threshold among the PCRs.
The pfdhfr gene analysis revealed the existence of seven
haplotypes: six associated with drug resistance profiles
(ARICNVI, ACICNVI, ACICNVL, ACNRNVI, ACNCNVI
and ACIRNVI) and one, from Paragominas locality, asso-
ciated with SP sensitivity (ACNCSVI). The drug resistance
pfdhfr haplotypes displayed up to three (50R + 51I and
108N; 51I + 108N and 164L, or 51I + 59R and 108N) out
of seven SNPs herein analysed. Concerning the pfdhps
gene, three single haplotypes (SGEGA, SGEAA, SGKAA),
displaying up to three (437G + 540E and 581G) out of the
five SNPs analysed were observed and, in this case, no
drug sensitive haplotype (SAKAA) was detected. In rela-
tion to pfcrt gene, two single haplotypes were observed:
the SVMNT CQ-resistant in 97% of the samples and the
CVMNK CQ-sensitive in the same sample from Paragom-
inas that showed the sensitive genotype to SP (pfdhfr
gene). All the three genes displayed at least one mixed
haplotype. These results are summarized in Table 1.
A multilocus analysis among the 47 samples showing sin-
gle haplotypes was performed. The pfdhfr + pfdhps + pfcrt
genes presented some usual haplotype associations as,
respectively, follows: ARICNVI + SGEGA + SVMNT
(42.5%), ACICNVL + SGEGA + SVMNT (27.6%), ARIC-Malaria Journal 2009, 8:156 http://www.malariajournal.com/content/8/1/156
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NVI + SGEAA + SVMNT (10.6%), ACICNVL + SGEAA +
SVMNT (6.3%) and ACICNVI + SGEGA + SVMNT (4.2%).
Other combinations such as ACICNVI + SGEAA + SVMNT
(2.13%), ACNCNVI + SGEGA + SVMNT (2.13%), ACNC-
SVI + SGEGA + CVMNK (2.13%) and ACNRNVI + SGKAA
+ SVMNT (2.13%) were observed only once. In all these
samples pfdhfr and pfdhps haplotypes were significantly
associated (p < 0.0001, Chi-square test); the same was true
for the only P. falciparum sample with CQ and SP sensitive
genotypes.
The five amino acid insertion between codons 30 and 31
of the pfdhfr gene named "Bolivia repeat" was found in 17
samples (one from Paragominas and 16 from Porto
Velho) and it was always associated with the leucine at the
codon 164, as previously reported [17].
In the two studied localities, the prevalence of the haplo-
types was different, for pfdhfr,  pfdhps  and  pfcrt  genes,
respectively. In Paragominas the predominant haplotypes
were ARICNVI, SGEGA and SVMNT while in Porto Velho,
the main ones were ACICNVL, SGEGA and SVMNT.
Discussion
Porto Velho displayed more allelic variation than Parago-
minas, especially for the pfdhps gene. No previous studies
were performed with P. falciparum samples from Parago-
minas, but two former studies had been performed in
Porto Velho using SP [2] or CQ [18] molecular markers.
In these reports, the authors detected the haplotypes
CVIET (pfcrt gene), AGEGA (pfdhps gene) and the S108T
(pfdhfr gene) that were not seen in the present study. How-
ever, pfdhps and pfdhfr haplotypes such as SGEAA, SGKAA,
Table 1: Pfcrt, pfdhfr and pfdhps haplotypes of P. falciparum parasites from Paragominas (PRG) and Porto Velho (PV), Brazilian 
Amazon.
Gene Haplotypes n (Locality) % Mutated codons
pfcrt SVMNT 63 (18 PRG and 45 PV) 97 2
CVMNK 1 (PRG) 1.5 0
C/S VMNT 1 (PV) 1.5 1 or 2
pfdhfr ARICNVI 27 (14 PRG and 13 PV) 52 3
ACICNVI 3 (1 PRG and 2 PV) 6 2
ACICNVL 17 (1 PRG and 16 PV) 33 3
ACNRNVI 1 (PV) 2 2
ACIRNVI 1 (PV) 2 3
ACNCNVI 1 (PRG) 2 1
ACNCSVI 1 (PRG) 2 0
ARICNV I/L 1 (PRG) 2 3 or 4
pfdhps SGEGA 41 (17 PRG and 24 PV) 65 3
SGEAA 9 (1 PRG and 8 PV) 14 2
SGKAA 10 (PV) 16 1
SGE A/G A 1 (PRG) 1.5 2 or 3
SGE/K AA 1 (PV) 1.5 1 or 2
SGE/K A/G A 1 (PV) 1.5 1, 2 or 3
Codon positions: pfcrt 72 to 76 (n = 65); pfdhfr 16, 50, 51, 59, 108, 140 and 164 (n = 52); and pfdhps 436, 437, 540, 581 and 613 (n = 63). The 
sensitive haplotypes are shown in bold characters and the mutated codons are underlined.Malaria Journal 2009, 8:156 http://www.malariajournal.com/content/8/1/156
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ACIRNVI and ACNRNVI, were described for the first time
in Brazil, while they had only previously been reported
from Tanzania [15] and India [19]. This might be due to
the considerable human movement in Porto Velho, not
only from other Amazonian (SA) regions, but also from
other areas in and outside Brazil, which could also explain
the detection of 16 P. falciparum infections harbouring the
"Bolivia repeat" against only one identified in Paragomi-
nas.
In Venezuela, a pfcrt wild type, similar to that found in
Paragominas, was also detected [20]. Differently from
Porto Velho, migration from the city of Paragominas to
other SA countries is very uncommon and, therefore, the
existence of a wild type parasite in Brazil seems not to be
related to parasite migration from other SA countries.
Since this infection harboured wild-type codons at pfcrt
72, 74, and 75, it is less probable that this haplotype cor-
respond to a single resistant allele that would have
reverted at the critical 76 codon (back mutation) and,
consequently, the more plausible explanation for this
finding is the presence of a bona fide sensitive allele.
Interestingly, in this study, an inferior prevalence of
mutated codons associated to SP resistance was perceived
when compared pfdhps  haplotypes with those already
observed in Brazil [2]. For instance, in 1998, Porto Velho
isolates displayed triple (53.4%) or quadruple (46.6%)
mutants in this gene, while single (22.7%), double
(18.2%) and triple (54.5%) mutants were detected in this
study, but no quadruple mutation was identified.
The present study is the first to document the existence of
CQ (CVMNK) and SP (ACNCSVI) sensitive haplotypes in
a Brazilian field sample. This is a noteworthy result,
because in Brazil the totally of P. falciparum parasites were
considered to be fully resistant to CQ and SP [18]. This
fact was not, however, surprising since the same phenom-
enon had already been reported in China and Malawi [9-
11]. Then, it could represent the reemergence of CQ and
SP sensitive parasites probably due to the spread of wild
type allele P. falciparum parasites [21]. Despite the rela-
tively small number of samples, it is suggested that the
number of sensitive parasite population detected remains
low because CQ is currently is still used for the treatment
of malaria vivax cases and SP or its analogues, are used for
anti-microbial therapy and, in this way, Plasmodium para-
sites could still be under drug pressure.
The finding of a single wild SP and CQ isolate will not
interfere in drug policy, but this detection is especially
remarkable because it might represent a tendency of sen-
sitive haplotypes re-emergence that could gain some
importance in the future.
Conclusion
These data reinforce the importance of performing molec-
ular surveillance by continuous chemoresistance assess-
ment, not only to predict shifts of drug resistance of
Plasmodium  populations following drug policy changes
but, particularly, to investigate the possibility of reintro-
duction of anti-malarial drugs, such as CQ and SP,
because of their low cost and wide availability. In this con-
text, the critical problem of P. falciparum chemoresistance
could be circumvented by turning-over the use of the
drugs, in order to enable the re-emergence of wild sensi-
tive parasites.
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